{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:50:59Z","timestamp":1785376259615,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012139","name":"Royal Marsden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.beha.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T02:25:42Z","timestamp":1559787942000},"page":"217-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["B and T cell prolymphocytic leukaemia"],"prefix":"10.1016","volume":"32","author":[{"given":"M.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","article-title":"Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Fran\u00e7ais d\u2019H\u00e9matologie Cellulaire","volume":"103","author":"Garand","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib2","volume":"4th","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.beha.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-003-0697-y","article-title":"T-cell prolymphocytic leukemia with autoimmune manifestations in Nijmegen breakage syndrome","volume":"82","author":"Michallet","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2019.06.001_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V87.2.423.bloodjournal872423","article-title":"Leukemia and lymphoma in ataxia telangiectasia","volume":"87","author":"Taylor","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1080\/1042819021000002884","article-title":"ATM mutations in sporadic lymphoid tumours","volume":"43","author":"Stankovic","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaad.2006.04.060","article-title":"T-cell prolymphocytic leukemia: an aggressive T-cell malignancy with frequent cutaneous tropism","volume":"55","author":"Magro","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2019.06.001_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1309\/93P42RNG5XBG3KBE","article-title":"T-cell prolymphocytic leukemia involving extramedullary sites","volume":"123","author":"Valbuena","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0165-4608(97)00410-X","article-title":"Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization","volume":"103","author":"Maljaei","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.beha.2019.06.001_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ajh.24679","article-title":"Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia","volume":"92","author":"Hu","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2019.06.001_bib12","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1073\/pnas.95.7.3885","article-title":"Deregulated expression of TCL1 causes T-cell leukemia in mice","volume":"95","author":"Virgilio","year":"1998","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.beha.2019.06.001_bib13","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2007-06-095570","article-title":"Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia","volume":"111","author":"Le Toriellec","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.22313","article-title":"Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker","volume":"55","author":"Stengel","year":"2016","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.beha.2019.06.001_bib15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02688-6","article-title":"Actionable perturbations of damage responses by TCL1\/ATM and epigenetic lesions form the basis of T-PLL","volume":"9","author":"Schrader","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2019.06.001_bib17","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.06.001_bib18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.13175","article-title":"Bendamustine is effective in T-Cell prolymphocytic leukaemia","volume":"168","author":"Herbaux","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","article-title":"High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia","volume":"111","author":"Herling","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib21","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/annonc\/mdx163","article-title":"Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)","volume":"28","author":"Jain","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.beha.2019.06.001_bib22","article-title":"New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine\u2013mitoxantrone\u2013cyclophosphamide\u2013alemtuzumab induction followed by alemtuzumab maintenance","author":"Pflug","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.06.001_bib23","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.27972","article-title":"Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia","volume":"119","author":"Hopfinger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2019.06.001_bib24","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody","volume":"15","author":"Pawson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.06.001_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.06.001_bib26","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.clml.2015.07.643","article-title":"Impact of alemtuzumab therapy and route of administration in T-prolymphocytic leukemia: a single-center experience","volume":"15","author":"Damlaj","year":"2015","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.beha.2019.06.001_bib28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European group for blood and marrow transplantation and the royal marsden consortium","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.06.001_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2019.06.001_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2018.01.009","article-title":"Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: a single-center experience","volume":"67","author":"Dholaria","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2019.06.001_bib33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/bmt.2016.305","article-title":"GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses","volume":"52","author":"Sellner","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2019.06.001_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0448-x","article-title":"EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)","author":"Wiktor-Jedrzejczak","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2019.06.001_bib35","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.06.001_bib36","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/leu.2017.252","article-title":"Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling","volume":"32","author":"Andersson","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.06.001_bib37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","article-title":"First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia","volume":"130","author":"Boidol","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5079","article-title":"Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia","volume":"7","author":"Hasanali","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beha.2019.06.001_bib39","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficientlymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.beha.2019.06.001_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2141.1974.tb06769.x","article-title":"Prolymphocytic leukaemia","volume":"27","author":"Galton","year":"1974","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2008.09.013","article-title":"The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication","volume":"33","author":"Pamuk","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2019.06.001_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.1987.tb06130.x","article-title":"The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"65","author":"Melo","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2013-10-533869","article-title":"B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma","volume":"124","author":"Van Der Velden","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib45","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.leu.2404238","article-title":"IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)","volume":"20","author":"Del Giudice","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.06.001_bib46","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2009.137","article-title":"B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures","volume":"23","author":"Del Giudice","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.06.001_bib47","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"p53 abnormalities in B-cell prolymphocytic leukemia","volume":"89","author":"Lens","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1309\/AJCPUBHM8U7ZFLOB","article-title":"Aberrations of MYC are a common event in B-cell prolymphocytic leukemia","volume":"142","author":"Flatley","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2019.06.001_bib49","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2018-99-115085","article-title":"Genetic characterization of B-cell prolymphocytic leukemia (B-PLL): a hierarchical prognostic model involving MYC and TP53 abnormalities on behalf of the Groupe Francophone de Cytogenetique hematologique (GFCH) and the French innovative leukemia organizat","volume":"132","author":"Chapiro","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.001_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199909093739","article-title":"B-Cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course","volume":"33","author":"Shvidel","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.06.001_bib51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/85.8.658","article-title":"Pentostatin in prolymphocytic leukemia: phase II trial of the European organization for research and treatment of cancer leukemia cooperative study group","volume":"85","author":"D\u00f6hner","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2019.06.001_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.1997.15.1.37","article-title":"Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia","volume":"15","author":"Saven","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.06.001_bib53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2011.01680.x","article-title":"Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"87","author":"Chow","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-008-0541-5","article-title":"A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia","volume":"88","author":"Tempescul","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2019.06.001_bib55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.20843","article-title":"Complete response to alemtuzumab in a patient with B prolymphocytic leukemia [7]","volume":"82","author":"Chaar","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2019.06.001_bib56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.06.001_bib57","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.06.001_bib58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.15151","article-title":"Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme","volume":"184","author":"Eyre","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.14224","article-title":"Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia","volume":"179","author":"Gordon","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.06.001_bib60","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bmt.1704991","article-title":"Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up","volume":"35","author":"Castagna","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2019.06.001_bib61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12185-014-1505-2","article-title":"Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission","volume":"99","author":"Arima","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.beha.2019.06.001_bib62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:09Z","timestamp":1761498369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619300350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1521692619300350"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.06.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B and T cell prolymphocytic leukaemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}